BCL11A and COVID-19: BCL11A is regarded as a potential therapeutic target for epilepsy (Wang et al., 2022)and was identified in a study in the UK as an independent variant that significantly predisposes individuals to critical COVID-19 (Kousathanas et al., 2022).